- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
142 |
D.J. Browning |
|
|
Fig. 7.1 The prevalence of diabetic macular edema by disease duration in (a) younger onset diabetics and (b) older onset diabetics. Reprinted with permission from Klein et al.17
of DME.14 The onset of diabetes in patients with type 1 disease is usually easy to define, in contrast to patients with type 2 disease. As a result, one can measure in a meaningful way the duration of type 1 diabetes before which DME is not seen; a duration of 7 years has been reported.15 Such is not possible in type 2 disease, in which it is common for patients to have the disease for years before diagnosis, and in which it is not rare to have patients present with blurred vision secondary to DME as the presenting sign that leads to the diagnosis of type 2 diabetes. The annual rate of incidence of DME has declined in recent years compared to earlier periods, perhaps as a result of tighter glycemic control. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy, the annual rates of incidence of DME for the intervals 1980–1982 to 1984–1986 and 1994–1996 to 2005–2007 were 2.3 and 0.9%, respectively.16 By comparison, the mean glycosylated hemoglobin values were 10.7 and 9.4%, respectively.16
The major ocular factor associated with DME and subclinical DME is diabetic retinopathy severity. Although DME can be seen at any level of diabetic retinopathy, increasing diabetic retinopathy severity
is associated with increasing prevalence of both DME and subclinical DME.3,16,18–20 The 14-year incidence
of DME increases from 25 to 37% as baseline retinopathy severity increases from mild to moderate nonproliferative diabetic retinopathy (NPDR).18 Point estimates of 4 and 15% for prevalence of subclinical DME in mild to moderate NPDR and severe NPDR to PDR, respectively, have been reported.20
7.2 Pathophysiology and Pathoanatomy
The reader should review Chapter 1 for a more detailed discussion of the pathophysiology of diabetic retinopathy. In this section, we emphasize only those aspects relevant to an understanding of diabetic macular edema.
7.2.1 Anatomy
The capillaries in the macula are distributed in two strata within the inner retina with the exception of the single-level arrangement bordering the foveal avascular zone (Fig. 7.2). This single level of capillaries
Fig. 7.2 Light micrograph of a section from the human macula. The line indicates a capillary comprising the foveal avascular zone border. The fovea lies to the left of the line. These capillaries are contained within the ganglion cell layer. Reprinted with permission from Iwasaki et al.21
7 Diabetic Macular Edema |
143 |
|
|
is found within the ganglion cell layer.21 Erythrocytes travel in the perifoveal capillaries in a pulsatile manner with speed in the range of 0.5–1.0 mm/s.22 Farther from the fovea, the two levels of capillaries are found within the nerve fiber–ganglion cell layer and the inner nuclear cell layer. The more superficial capillary network is closer to the arteries, and the deeper network is closer to the venules. Arising from the disk and extending within the nerve fiber layer along the superotemporal and inferotemporal vascular arcades is the radial peripapillary capillary network, which seems to have sparse connections to the superficial capillary network of the ganglion cell layer (Fig. 7.3).23 The outer retina throughout the macula is avascular and receives oxygenation by diffusion from the deeper choriocapillaris.24 The maximum distance between capillaries in the inner retina is approximately 65–100 mm and the estimated maximal diffusion distance in the human macula consistent with normal function has been estimated to be approximately half this distance or approximately
45 mm.21 Eighty percent of microaneurysms, which seem to be a microvascular response to vascular endothelial growth factor (VEGF) generated from hypoxic retinal tissue, originate in the inner nuclear layer and its border zones.25 The larger microaneurysms tend to occur in this zone and smaller ones in the nerve fiber–ganglion cell layers. Microaneurysms range in size from 13 to 136 mm.25 Microaneurysms are particularly frequent on the edges of nonperfused retina, consistent with the hypothesis that they are a secondary reaction to hypoxia and increased local vascular endothelial growth factor concentration, and not a primary change in diabetic retinopathy (Figs. 7.4 and 7.5). As defined by fluorescein angiography, microaneurysms in DME do not have a regional clustering. One study reported that, on average, 3% of the leaking microaneurysms discerned by fluorescein angiography were present in the central circular zone of 1-mm diameter, whereas the percentages in the inferior, nasal, superior, and temporal zones as defined by the Early Treatment Diabetic
Fig. 7.3 Diagram indicating the distribution of the radial peripapillary capillary network, its location in the inner retina (primarily nerve fiber layer), and its sparse connections with deeper levels of capillaries
144 |
D.J. Browning |
|
|
Fig. 7.4 The left panel (a) illustrates the foveal avascular zone (FAZ) of a normal macula from a cynomolgus monkey which has a similar anatomy to the human macula. The right panel (b) illustrates changes induced by intravitreal injection
of VEGF. The microaneuryms resemble those seen in dia-
betic retinopathy. Reprinted with permission from Tolentino et al.26
avascularity at the center of the macula. In other regions of the macula, edema fluid can escape the extracellular space in two ways – outward to the choroid via the pumping mechanism of the retinal pigment epithelium, and back into the intravascular space through the walls of capillaries, the direction reverse to salt and water egress from intra to extravascular space in the more proximal microvasculature (Fig. 7.6). At the center of the macula, the only mechanism is that of the retinal pigment epithelial
Fig. 7.5 The circled zone shows large microaneurysms and some dot hemorrhages that border an ischemic, whitened zone of retina
Retinopathy Study (ETDRS) grid were 26, 25, 23, and 24%, respectively.27 The relationship of microaneurysms and DME is not straightforward. The retina is not necessarily thickened adjacent to micro-
aneurysms and not all microaneurysms are leaky.28,29 There is no increase in total microaneur-
ysms or leaking aneurysms per unit area in progressively more thickened retina.29 Nevertheless, abla-
tion of leaky microaneurysms clearly improves DME.4,30
In center-involved macular edema, it is common for the central macula, including the foveal vascular zone, to be thickest, an inversion of the normal relationship. Although the underlying reason has not been established, one hypothesis is based on the
Fig. 7.6 Diagram indicating one pathway for salt and water within the retina. Under the influence of higher intravascular pressure in the arterioles, salt and water pass out of the vessels (transudate) and into the extracellular space of the retina, then returning to the intravascular space in part by entering the venular side of the circulation which has a lower intravascular pressure
7 Diabetic Macular Edema |
145 |
|
|
(RPE) pump, which may explain the greater accumulation of edema fluid and increased retinal thickness at this location (Fig. 7.7). A fundus sign of the preferential accumulation of edema fluid in the center of the macula is the appearance of the macular lipid star commonly seen in cases of DME (Fig. 7.8). As the RPE pumps salt and water from the retinal extracellular space to the choroid, lipoproteins contained in
the extracellular fluid are left behind as yellow exudates that must be cleared much more slowly by macrophages. In 15–30% of cases of DME, a serous retinal detachment is present which is usually localized under the fovea. Although the explanation for the subfoveal location of fluid is conjectural, one
possibility posits an effect of impaired subfoveal choroidal circulation in DME.31,32
Fig. 7.7 Diagram indicating the different situation of the center ofthemacula.Thereisnovenoussideofthevasculatureinthisone location in the retina, thus salt and water can exit the vascular space from the capillaries, but can only leave the extracellular spaceviatheactionoftheretinalpigmentepithelialpump,andnot via reentry into the venules which are missing in this location
Fig. 7.8 A macular lipid star is a common fundus sign in diabetic macular edema and indicates that the center of the macula is a preferential site for accumulation of extracellular fluid
The Retinal Pigment Epithelial Pump
In most discussion of diabetic macular edema, the role of the retinal pigment epithelial pump is comparatively neglected, because it is difficult to study. Extracellular fluid travels from the retina outward toward the choroid primarily under the influence of the RPE pump action.33 Figure 7.9 illustrates the current conception of ionic and fluid transport across the RPE into the choroid. An active sodium–potassium pump is present on the apical membrane of the RPE that exchanges three sodium ions toward the extracellular space for two potassium ions toward the RPE cytoplasm. An electrochemical gradient is generated by the asymmetry in the ionic exchange ratio, and this gradient powers other active transport mechanisms of which several have been described. Independent sodium–potassium-chloride and sodium-bicarbonate co-transport sites exist on the apical RPE membrane. An apical sodium-proton exchanger exists. These actively concentrate chloride and bicarbonate intracellularly. On the basal RPE membrane, separate sites exist for chloride and potassium ion egress as well as for a chloride–bicarbonate co-transporter.33,34 Physiologic and pharmacologic modulation of fluid transport across the RPE is possible. Hypoxia decreases active transport across the RPE. Epinephrine applied to the apical RPE surface increases RPE transport. Acetazolamide increases transport, whereas furosemide decreases it. In extremely high concentrations not achieved clinically, digoxin reduces RPE transport. The possible influence of drugs commonly taken by patients with diabetes in altering the response to DME therapy has been completely unexplored to date.
146 |
D.J. Browning |
|
|
Fig. 7.9 Model of the retinal pigment epithelial pumping mechanism. The RPE cells are connected by zonula occludens which restrict the extracellular flow of ions and water back from the choroid toward the retina via the intercellular space between RPE cells. The primary energy dependent pump is the apical (retina side) sodium–potassium, electrogenic pump (left side of the cell). Other active transport systems derive the energy they require to run from the
electrochemical gradients built up by this primary pump. In the apical membrane, independent sodium-bicarbonate, sodium–potassium-chloride, chloride–bicarbonate, and sodium-lactate–water transport sites have been described. In the basal membrane, a chloride–bicarbonate co-transporter exists. Passive conductance channels for potassium and chloride also exist as shown. Adapted with permission from La Cour34 and Quintyn33
Tight junctions occur between capillary endothelial cells of the retina, the basis of the inner blood– retina barrier, and between the lateral walls of RPE cells, the outer blood–retina barrier. Diabetes causes a redistribution of occludin within the tight junctions of retinal vascular endothelium which may be the histologic correlate of the altered blood–retina barrier.35 In a rat model of diabetes, the early breakdown of the blood–retinal barrier is selective for small venules and capillaries of the inner retina with sparing of the arterioles.36 The inner blood–retina barrier rather than outer blood–retina barrier (RPE layer) breakdown is considered to be more important in the mechanism of DME even though RPE lesions can be seen shortly
after induction of diabetes in the streptozotocintreated rat model of the disease.37,38 The amount
of heparin sulfate proteoglycan is increased in the vascular endothelium of diabetic eyes compared to
nondiabetic eyes. Muller cells are important in transporting water from the extracellular space into the retinal capillaries of the inner retina.39 Their density in the macaque monkey is five times greater in the parafovea than the retinal periphery.40 The colocalization of Muller cells with the retinal regions most affected by edema suggests that Muller cell dysfunction contributes to DME. Moreover, Muller cells proliferate in epiretinal membranes, which can exert traction on microvessels and possibly increase their permeability, exacerbating macular edema. Astrocytes, which wrap their end feet around microvessels, decrease their production of glial fibrillary acidic protein in diabetes, which may be important in the altered blood–retina barrier.35 Within the retina, the synaptic portion of the outer plexiform layer and the entire inner plexiform layer comprise the two highest
